Viola A Heinzelmann-Schwarz

List of Publications by Year
in descending order

88 papers	4,682 citations	147726 31 h-index	106281 65 g-index
91 all docs	91 docs citations	91 times ranked	8136 citing authors

#	ARTICLE	IF	CITATIONS
1	Neutrophils escort circulating tumour cells to enable cell cycle progression. Nature, 2019, 566, 553-557.	13.7	804
2	Circulating Tumor Cell Clustering Shapes DNA Methylation to Enable Metastasis Seeding. Cell, 2019, 176, 98-112.e14.	13.5	578
3	Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells. Journal of Clinical Investigation, 2018, 128, 4912-4923.	3.9	214
4	Overexpression of the Cell Adhesion Molecules DDR1, Claudin 3, and Ep-CAM in Metaplastic Ovarian Epithelium and Ovarian Cancer. Clinical Cancer Research, 2004, 10, 4427-4436.	3.2	189
5	Careful Selection of Reference Genes Is Required for Reliable Performance of RT-qPCR in Human Normal and Cancer Cell Lines. PLoS ONE, 2013, 8, e59180.	1.1	185
6	Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy. Science Translational Medicine, 2019, 11, .	5.8	178
7	No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting. Gynecologic Oncology, 2011, 121, 487-491.	0.6	151
8	Specific Glycosylation of Membrane Proteins in Epithelial Ovarian Cancer Cell Lines: Glycan Structures Reflect Gene Expression and DNA Methylation Status. Molecular and Cellular Proteomics, 2014, 13, 2213-2232.	2.5	134
9	Microtubule-Depolymerizing Agents Used in Antibodyâ€“Drug Conjugates Induce Antitumor Immunity by Stimulation of Dendritic Cells. Cancer Immunology Research, 2014, 2, 741-755.	1.6	134
10	Protein Significance Analysis in Selected Reaction Monitoring (SRM) Measurements. Molecular and Cellular Proteomics, 2012, 11, M111.014662.	2.5	124
11	The metastatic spread of breast cancer accelerates during sleep. Nature, 2022, 607, 156-162.	13.7	114
12	A distinct molecular profile associated with mucinous epithelial ovarian cancer. British Journal of Cancer, 2006, 94, 904-913.	2.9	102
13	LRP1B Deletion in High-Grade Serous Ovarian Cancers Is Associated with Acquired Chemotherapy Resistance to Liposomal Doxorubicin. Cancer Research, 2012, 72, 4060-4073.	0.4	100
14	URI Is an Oncogene Amplified in Ovarian Cancer Cells and Is Required for Their Survival. Cancer Cell, 2011, 19, 317-332.	7.7	77
15	The Wnt Gatekeeper SFRP4 Modulates EMT, Cell Migration and Downstream Wnt Signalling in Serous Ovarian Cancer Cells. PLoS ONE, 2013, 8, e54362.	1.1	77
16	Serum antiglycan antibody detection of nonmucinous ovarian cancers by using a printed glycan array. International Journal of Cancer, 2012, 130, 138-146.	2.3	71
17	The Tumor Profiler Study: integrated, multi-omic, functional tumor profiling for clinical decision support. Cancer Cell, 2021, 39, 288-293.	7.7	71
18	The microtubule-depolymerizing agent ansamitocin P3 programs dendritic cells toward enhanced anti-tumor immunity. Cancer Immunology, Immunotherapy, 2014, 63, 925-938.	2.0	60

#	Article	IF	Citations
19	The non-canonical Wnt ligand, Wnt5a, is upregulated and associated with epithelial to mesenchymal transition in epithelial ovarian cancer. Gynecologic Oncology, 2014, 134, 338-345.	0.6	60
20	Targeting the ROR1 and ROR2 receptors in epithelial ovarian cancer inhibits cell migration and invasion. Oncotarget, 2015, 6, 40310-40326.	0.8	58
21	The E3 ubiquitin ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitro. British Journal of Cancer, 2008, 98, 1085-1093.	2.9	56
22	Loss of Secreted Frizzled-Related Protein 4 Correlates with an Aggressive Phenotype and Predicts Poor Outcome in Ovarian Cancer Patients. PLoS ONE, 2012, 7, e31885.	1.1	51
23	A clinicopathological review of 33 patients with vulvar melanoma identifies c-KIT as a prognostic marker. International Journal of Molecular Medicine, 2014, 33, 784-794.	1.8	43
24	MELK expression in ovarian cancer correlates with poor outcome and its inhibition by OTSSP167 abrogates proliferation and viability of ovarian cancer cells. Gynecologic Oncology, 2017, 145, 159-166.	0.6	42
25	A Targeted Mass Spectrometry Strategy for Developing Proteomic Biomarkers: A Case Study of Epithelial Ovarian Cancer. Molecular and Cellular Proteomics, 2019, 18, 1836-1850.	2.5	42
26	The glycosphingolipid P1 is an ovarian cancer-associated carbohydrate antigen involved in migration. British Journal of Cancer, 2014, 111, 1634-1645.	2.9	40
27	Reliable in vitro studies require appropriate ovarian cancer cell lines. Journal of Ovarian Research, 2014, 7, 60.	1.3	39
28	Comparison of printed glycan array, suspension array and ELISA in the detection of human anti-glycan antibodies. Glycoconjugate Journal, 2011, 28, 507-517.	1.4	38
29	Antibody-based immunotherapy for ovarian cancer: where are we at?. Annals of Oncology, 2014, 25, 322-331.	0.6	38
30	Transition of Mesenchymal and Epithelial Cancer Cells Depends on Î±1-4 Galactosyltransferase-Mediated Glycosphingolipids. Cancer Research, 2018, 78, 2952-2965.	0.4	35
31	Fibroblast activation protein-targeted-4-1BB ligand agonist amplifies effector functions of intratumoral T cells in human cancer. , 2020, 8, e000238.		35
32	Collagen-rich omentum is a premetastatic niche for integrin Î±2-mediated peritoneal metastasis. ELife, 2020, 9, .	2.8	35
33	Meta-Analysis of Microarray Data IdentifiesGAS6Expression as an Independent Predictor of Poor Survival in Ovarian Cancer. BioMed Research International, 2013, 2013, 1-9.	0.9	33
34	Epigenetic activation of MGAT3 and corresponding bisecting GlcNAc shortens the survival of cancer patients. Oncotarget, 2016, 7, 51674-51686.	0.8	33
35	Regulation of invasion and peritoneal dissemination of ovarian cancer by mesothelin manipulation. Oncogenesis, 2020, 9, 61.	2.1	30
36	Cancer Predisposition Cascade Screening for Hereditary Breast/Ovarian Cancer and Lynch Syndromes in Switzerland: Study Protocol. JMIR Research Protocols, 2017, 6, e184.	0.5	30

#	Article	IF	Citations
37	Multiplex suspension array for human anti-carbohydrateantibody profiling. Analyst, The, 2011, 136, 560-569.	1.7	29
38	Letrozole may be a valuable maintenance treatment in high-grade serous ovarian cancer patients. Gynecologic Oncology, 2018, 148, 79-85.	0.6	29
39	Expression of inhibitory receptors on intratumoral T cells modulates the activity of a T cell-bispecific antibody targeting folate receptor. OncoImmunology, 2016, 5, e1062969.	2.1	27
40	Tumor-Associated Glycans and Their Role in Gynecological Cancers: Accelerating Translational Research by Novel High-Throughput Approaches. Metabolites, 2012, 2, 913-939.	1.3	26
41	PEGylation of microbead surfaces reduces unspecific antibody binding in glycan-based suspension array. Journal of Immunological Methods, 2014, 412, 42-52.	0.6	26
42	A forgotten disease: Pelvic congestion syndrome as a cause of chronic lower abdominal pain. PLoS ONE, 2019, 14, e0213834.	1.1	26
43	Blood Plasma-Derived Anti-Glycan Antibodies to Sialylated and Sulfated Glycans Identify Ovarian Cancer Patients. PLoS ONE, 2016, 11, e0164230.	1.1	25
44	Long-term quality of life, satisfaction, pelvic floor symptoms and regret after colpocleisis. Archives of Gynecology and Obstetrics, 2016, 294, 999-1003.	0.8	25
45	Tissue glycomics distinguish tumour sites in women with advanced serous adenocarcinoma. Molecular Oncology, 2017, 11, 1595-1615.	2.1	24
46	The special role of ultrasound for screening, staging and surveillance of malignant ovarian tumors: distinction from other methods of diagnostic imaging. Archives of Gynecology and Obstetrics, 2014, 289, 491-498.	0.8	23
47	L1 Cell Adhesion Molecule Confers Radioresistance to Ovarian Cancer and Defines a New Cancer Stem Cell Population. Cancers, 2020, 12, 217.	1.7	23
48	Naturally occurring anti-glycan antibodies binding to Globo H-expressing cells identify ovarian cancer patients. Journal of Ovarian Research, 2017, 10, 8.	1.3	21
49	Challenges and Opportunities for Cancer Predisposition Cascade Screening for Hereditary Breast and Ovarian Cancer and Lynch Syndrome in Switzerland: Findings from an International Workshop. Public Health Genomics, 2018, 21, 121-132.	0.6	20
50	Denosumab treatment is associated with the absence of circulating tumor cells in patients with breast cancer. Breast Cancer Research, 2018, 20, 141.	2.2	20
51	Low meprin Â expression differentiates primary ovarian mucinous carcinoma from gastrointestinal cancers that commonly metastasise to the ovaries. Journal of Clinical Pathology, 2007, 60, 622-626.	1.0	19
52	Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers. Gynecologic Oncology, 2019, 155, 262-269.	0.6	19
53	Role of p53 and ATM in photodynamic therapy-induced apoptosis. Lasers in Surgery and Medicine, 2003, 33, 182-189.	1.1	18
54	Alterations in the mitochondrial responses to PENAO as a mechanism of resistance in ovarian cancer cells. Gynecologic Oncology, 2015, 138, 363-371.	0.6	17

#	Article	IF	Citations
55	Clinicopathological features of women with epithelial ovarian cancer and double heterozygosity for BRCA1 and BRCA2: A systematic review and case report analysis. Gynecologic Oncology, 2020, 156, 377-386.	0.6	14
56	Proteogenomic studies in epithelial ovarian cancer: established knowledge and future needs. Biomarkers in Medicine, 2009, 3, 743-756.	0.6	13
57	Expression of GBGT1 is epigenetically regulated by DNA methylation in ovarian cancer cells. BMC Molecular Biology, 2014, 15, 24.	3.0	13
58	Nivolumab in chemotherapy-resistant cervical cancer: report of a vulvitis as a novel immune-related adverse event and molecular analysis of a persistent complete response. , 2019, 7, 281.		10
59	Impact of breast cancer family history on tumor detection and tumor size in women newly-diagnosed with invasive breast cancer. Familial Cancer, 2014, 13, 99-107.	0.9	9
60	Improved Detection Rate of Ovarian Cancer Using a 2-Step Triage Model of the Risk of Malignancy Index and Expert Sonography in an Outpatient Screening Setting. International Journal of Gynecological Cancer, 2016, 26, 1062-1069.	1.2	9
61	ABO blood groups as a prognostic factor for recurrence in ovarian and vulvar cancer. PLoS ONE, 2018, 13, e0195213.	1.1	9
62	Outcome in serous ovarian cancer is not associated with LATS expression. Journal of Cancer Research and Clinical Oncology, 2019, 145, 2737-2749.	1.2	8
63	Intention to Inform Relatives, Rates of Cascade Testing, and Preference for Patient-Mediated Communication in Families Concerned with Hereditary Breast and Ovarian Cancer and Lynch Syndrome: The Swiss CASCADE Cohort. Cancers, 2022, 14, 1636.	1.7	8
64	Impact of the new FIGO 2013 classification on prognosis of stage I epithelial ovarian cancers. Cancer Management and Research, 2018, Volume 10, 4709-4718.	0.9	7
65	An interdisciplinary team-training protocol for robotic gynecologic surgery improves operating time and costs: analysis of a 4-year experience in a university hospital setting. Journal of Robotic Surgery, 2022, 16, 89-96.	1.0	7
66	Using a Tailored Digital Health Intervention for Family Communication and Cascade Genetic Testing in Swiss and Korean Families With Hereditary Breast and Ovarian Cancer: Protocol for the DIALOGUE Study. JMIR Research Protocols, 2021, 10, e26264.	0.5	7
67	Comparison of 2D 4K vs. 3D HD laparoscopic imaging systems using a pelvitrainer model: a randomized controlled study. Updates in Surgery, 2022, 74, 1137-1147.	0.9	7
68	Should MMMT still be treated with adjuvant taxane-based combination chemotherapy?. Journal of Cancer Research and Clinical Oncology, 2020, 146, 695-704.	1.2	5
69	Aromatase inhibitor maintenance therapy in high grade advanced ovarian cancer to delay first recurrence.. Journal of Clinical Oncology, 2017, 35, 5515-5515.	0.8	5
70	Patient-derived and artificial ascites have minor effects on MeT-5A mesothelial cells and do not facilitate ovarian cancer cell adhesion. PLoS ONE, 2020, 15, e0241500.	1.1	5
71	Genetic Literacy and Communication of Genetic Information in Families Concerned with Hereditary Breast and Ovarian Cancer: A Cross-Study Comparison in Two Countries and within a Timeframe of More Than 10 Years. Cancers, 2021, 13, 6254.	1.7	5
72	Maintenance Therapy with Aromatase Inhibitor in epithelial Ovarian Cancer (MATAO): study protocol of a randomized double-blinded placebo-controlled multi-center phase III Trial. BMC Cancer, 2022, 22, 508.	1.1	4

#	Article	IF	Citations
73	How does colpocleisis for pelvic organ prolapse in older women affect quality of life, body image, and sexuality? A critical review of the literature. Women's Health, 2022, 18, 174550572211110.	0.7	4
74	Endocrine Therapy in Epithelial Ovarian Cancer (EOC) New Insights in an Old Target: A Mini Review. Journal of Cancer Clinical Trials, 2018, 03, .	0.2	3
75	Management of Human Papillomavirus-Related Gynecological Malignancies. Current Problems in Dermatology, 2014, 45, 216-224.	0.8	2
76	Fibrin-thrombin sealant does not reduce lymphocele formation in patients with inguinofemoral lymphadenectomy for vulvar cancer . Cancer Management and Research, 2019, Volume 11, 3575-3582.	0.9	2
77	Spontaneous Remission of Severe Systemic Langerhans Cell Histiocytosis with Bladder Involvement: A Case Study. Case Reports in Oncology, 2018, 10, 876-884.	0.3	1
78	Highâ€grade serous peritoneal cancer follows a high stromal response signature and shows worse outcome than ovarian cancer. Molecular Oncology, 2021, 15, 91-103.	2.1	1
79	L1CAM is not a reliable predictor for lymph node metastases in endometrial cancer, but L1CAM positive patients benefit from radiotherapy. Journal of Cancer, 2021, 12, 6401-6410.	1.2	1
80	Ovarian cancer in Switzerland: incidence and treatment according to hospital registry data. Swiss Medical Weekly, 2018, 148, w14647.	0.8	1
81	Managing Cancer as a Family Disease - Feasibility, Satisfaction and Family Functioning after Short-Time Counselling for Families with Parental Cancer. Family Journal, 0, , 106648072110524.	0.7	1
82	Reply to comment on: Wiser et al. Ovarian cancer in Switzerland: incidence and treatment according to hospital registry data. Swiss Med Wkly.2018;148:w14647. Swiss Medical Weekly, 2020, 150, w20180.	0.8	1
83	The double S technique to achieve aesthetic flat closure after conventional mastectomy. World Journal of Surgical Oncology, 2022, 20, 42.	0.8	1
84	Comment on the letter: The mass cannot be classified as malignant. Archives of Gynecology and Obstetrics, 2015, 291, 475-475.	0.8	0
85	Diaphragmatic smears are not of additional benefit in the detection of peritoneal spread in gynecological cancers. Experimental and Therapeutic Medicine, 2018, 15, 4199-4204.	0.8	0
86	Need for radiological staging in breast cancer patients with axillary micrometastases.. Journal of Clinical Oncology, 2014, 32, e12026-e12026.	0.8	0
87	Should MMMT of the endometrium/ovary be treated with anthracycline instead of taxane based chemotherapy?. Journal of Clinical Oncology, 2017, 35, 5563-5563.	0.8	0
88	Diagnosis of Epithelial Ovarian, Fallopian Tubal and Peritoneal Surface Cancers. , 2021, , 348-356.		0